PharmaNutra SpA (PHN) AI Stock Analysis

• Market Cap: €425.48M
• Dividend Yield: 2.25%
• Average Volume (3M): 37.38K
• Price to Earnings (P/E): 25.0
• Beta (1Y): 0.42
• Revenue Growth: 13.75%
• EPS Growth: 16.66%
• Country: IT
• Employees: 118
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.70
• Shares Outstanding: 9,680,977
• 10 Day Avg. Volume: 20,859
• 30 Day Avg. Volume: 37,383
• PEG Ratio: 1.05
• Price to Book (P/B): 8.41
• Price to Sales (P/S): 4.50
• P/FCF Ratio: 32.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €81.00
• Price Target Upside: 65.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: €52.00 ▲(6.23% Upside)

PharmaNutra SpA's overall stock score is driven by its strong financial performance, particularly in revenue growth and profit margins. However, technical analysis presents mixed signals, and the valuation suggests potential overvaluation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and effective sales strategy, supporting long-term business expansion and stability.

Profit Margins

High profit margins suggest efficient operations and pricing power, which can sustain profitability and competitive advantage over time.

Balance Sheet Health

A strong balance sheet with manageable debt levels ensures financial flexibility and resilience against economic fluctuations.

Negative Factors

Free Cash Flow Decline

Declining free cash flow growth can limit the company's ability to invest in growth opportunities and meet financial obligations, impacting long-term sustainability.

Operating Cash Flow Constraints

Cash flow constraints may hinder operational efficiency and limit the company's capacity to fund new projects or manage unexpected expenses.

Gross Profit Margin Decline

A declining gross profit margin could signal rising costs or pricing pressures, potentially affecting profitability if the trend continues.

PharmaNutra SpA Business Overview & Revenue Model

Company Description

PharmaNutra SpA is an Italian pharmaceutical company focused on developing and marketing innovative nutritional supplements and medical devices. The company operates primarily in the healthcare sector, offering a range of products designed to improve health and wellness, with a particular emphasis on minerals, vitamins, and functional ingredients. PharmaNutra's core products include iron-based supplements and other formulations that target various health conditions, enhancing both performance and recovery for athletes and individuals with specific nutritional needs.

How the Company Makes Money

PharmaNutra generates revenue through the sale of its nutritional supplements and medical devices to both consumers and healthcare professionals. The company's revenue model is primarily driven by direct sales, partnerships with pharmacies, and collaborations with healthcare providers. Key revenue streams include the distribution of its proprietary formulations in domestic and international markets, where it leverages its research and development capabilities to innovate and expand its product line. Additionally, PharmaNutra benefits from strategic partnerships with other health-focused organizations that enhance its market reach and credibility, contributing to its financial performance.

PharmaNutra SpA Financial Statement Overview

Summary

PharmaNutra SpA demonstrates strong financial performance with consistent revenue growth and solid profit margins. The balance sheet is stable with a reasonable debt level and strong return on equity. However, the decline in free cash flow growth and operating cash flow coverage ratio in the TTM period could pose challenges.

Income Statement

PharmaNutra SpA shows strong revenue growth with a TTM increase of 3.01% and consistent annual growth. The company maintains healthy profit margins, with a TTM gross profit margin of 66.81% and a net profit margin of 13.77%. EBIT and EBITDA margins are also robust, indicating efficient operations. However, there is a slight decline in gross profit margin compared to the previous year, which could be a point of concern.

Balance Sheet

The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.37 in the TTM period, showing improvement from previous years. Return on equity is strong at 27.32%, indicating effective use of shareholder funds. The equity ratio is healthy, suggesting a solid capital structure. However, the increase in total debt over the years needs monitoring.

Cash Flow

Cash flow analysis reveals a significant decline in free cash flow growth in the TTM period, down by 60.35%, which is concerning. The operating cash flow to net income ratio is below 1, indicating potential cash flow constraints. Despite this, the free cash flow to net income ratio remains strong at 83.26%, suggesting that the company generates sufficient cash relative to its net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	122.79M	116.15M	101.03M	83.39M	68.14M	58.48M
Gross Profit	91.29M	82.79M	48.95M	30.17M	32.15M	21.30M
EBITDA	32.39M	32.01M	26.53M	24.61M	19.84M	14.28M
Net Income	16.90M	16.61M	12.83M	15.05M	13.77M	14.07M
Balance Sheet
Total Assets	115.67M	117.47M	112.44M	100.16M	71.36M	51.71M
Cash, Cash Equivalents and Short-Term Investments	15.68M	29.10M	25.12M	26.86M	33.94M	20.80M
Total Debt	22.13M	24.27M	28.02M	17.73M	6.35M	1.66M
Total Liabilities	54.43M	55.27M	58.04M	49.21M	26.27M	13.98M
Stockholders Equity	61.24M	62.16M	54.41M	50.95M	45.08M	37.73M
Cash Flow
Free Cash Flow	8.21M	16.25M	-1.16M	-8.69M	15.43M	10.46M
Operating Cash Flow	12.32M	20.50M	12.09M	14.47M	20.41M	11.79M
Investing Cash Flow	-3.09M	-2.21M	-14.70M	-23.71M	-5.54M	-598.00K
Financing Cash Flow	-15.70M	-21.59M	-516.00K	1.89M	-1.92M	-4.73M

PharmaNutra SpA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 48.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Negative. The current price of 48.95 is above the 20-day moving average (MA) of 46.71, above the 50-day MA of 45.22, and above the 200-day MA of 48.49, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 39.90 is Neutral, neither overbought nor oversold. The STOCH value of 16.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHN.

PharmaNutra SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHN	71 Outperform	€425.48M	24.98	―	2.25%	13.75%	16.66%
PHIL	70 Outperform	€719.37M	21.63	45.54%	―	3346.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%